Sort
10,766 grants matching “checkpoint inhibitor”
The Duke Preclinical Research Resources for Quantitative Imaging Biomarkers
$577,389Cristian T Badea · Duke University · U24 · FY2021 · CA
Mechanism of estrogen independent proliferation in ER+ breast cancer cells
$577,234Andrea Hope Bild · Beckman Research Institute/City Of Hope · U01 · FY2025 · CA
Discovery of Glutaryl-CoA Dehydrogenase inhibitors for melanoma and pancreatic cancer
$577,198Eduard A. Sergienko · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2024 · CA
Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapy
$577,137Christiane Querfeld · Beckman Research Institute/City Of Hope · R01 · FY2019 · CA
Reprogramming PDAC tumor microenvironment to improve immunotherapy
$577,095Rakesh K. Jain · Massachusetts General Hospital · U01 · FY2021 · CA
Reprogramming PDAC tumor microenvironment to improve immunotherapy
$577,095Rakesh K. Jain · Massachusetts General Hospital · U01 · FY2020 · CA
Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer
$577,069David P Carbone · Ohio State University · R01 · FY2021 · CA
Understanding Efficacy and Fe(II)-Promoted Activation of 1,2,4-Trioxolanes in Cancer
$577,035Eric Collisson · University Of California, San Francisco · R01 · FY2021 · CA
Targeting tumor microenvironment by nanoimmunodrugs for glioma treatment
$577,033Alexander V Ljubimov · Cedars-Sinai Medical Center · R01 · FY2023 · CA
Understanding how adrenergic signaling influences immune contexture of tumors and the efficacy of checkpoint inhibitors
$576,552Elizabeth Repasky · Roswell Park Cancer Institute Corp · R01 · FY2018 · CA
Advancing the translatability of mouse models for cancer immunotherapy
$576,547Rosemary J Akhurst · University Of California, San Francisco · R01 · FY2019 · CA
Genetically Engineered Mouse Models to Study Melanoma Genesis and Progression
$576,453Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Preclinical Mouse Models for Studying Immune Checkpoint Inhibitor Response
$576,453Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
The role of Galectin-1 in shaping the immune suppressive landscape in head and neck cancer
$576,429Quynh-Thu X Le · Stanford University · R01 · FY2025 · DE
The role of Galectin-1 in shaping the immune suppressive landscape in head and neck cancer
$576,376Quynh-Thu X Le · Stanford University · R01 · FY2023 · DE
Quantitative Multimodal Imaging Biomarkers for Combined Locoregional and Immunotherapy of Liver Cancer
$576,314James S Duncan · Yale University · R01 · FY2023 · CA
Exosomes as carriers of cancer therapeutics
$576,222Rajagopal Ramesh · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2021 · CA
EPIGENETIC EFFECTORS OF TUMOR RESPONSE TO IMMUNE CHECKPOINT INHIBITORS
$576,000The Univeristy Of Texas M.D. Anderson Cancer Center · · FY2017 · Department of the Army
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer
$575,892Timothy R Donahue · University Of California Los Angeles · R01 · FY2024 · CA
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
$575,716Farrokh Dehdashti · Washington University · R01 · FY2019 · CA
Peptoid conjugates targeting prostate cancer
$575,698Michael J Garabedian · New York University School Of Medicine · R01 · FY2025 · CA
Immune correlates of LTBI in HIV-exposed infants
$575,685Savita Pahwa · University Of Miami School Of Medicine · R01 · FY2023 · AI
Phase II Study of ASTX727 in Patients with PRC2 loss Malignant Peripheral Nerve Sheath Tumor (MPNST)
$575,542Ping Chi · Sloan-Kettering Inst Can Research · R01 · FY2023 · FD
Phase II Study of ASTX727 in Patients with PRC2 loss Malignant Peripheral Nerve Sheath Tumor (MPNST)
$575,542Ping Chi · Sloan-Kettering Inst Can Research · R01 · FY2025 · FD
Identification of small molecule inhibitors to exonuclease 1 for breast cancer treatment
$575,395Binghui Shen · Beckman Research Institute/City Of Hope · U01 · FY2023 · CA